VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-830-3031
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.36 million
Profitability
Miscellaneous
Employees108
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions
What is VBI Vaccines' stock symbol?
VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."
How were VBI Vaccines' earnings last quarter?
VBI Vaccines Inc (NASDAQ:VBIV) posted its earnings results on Friday, August, 9th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. The biopharmaceutical company had revenue of $0.64 million for the quarter, compared to analyst estimates of $0.60 million. VBI Vaccines had a negative return on equity of 73.80% and a negative net margin of 1,582.45%. View VBI Vaccines' Earnings History.
When is VBI Vaccines' next earnings date?
What price target have analysts set for VBIV?
2 equities research analysts have issued twelve-month price targets for VBI Vaccines' shares. Their predictions range from $5.00 to $5.00. On average, they anticipate VBI Vaccines' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 861.5% from the stock's current price. View Analyst Price Targets for VBI Vaccines.
What is the consensus analysts' recommendation for VBI Vaccines?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VBI Vaccines.
Has VBI Vaccines been receiving favorable news coverage?
News articles about VBIV stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. VBI Vaccines earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for VBI Vaccines.
Are investors shorting VBI Vaccines?
VBI Vaccines saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 3,510,000 shares, a decline of 23.0% from the August 30th total of 4,560,000 shares. Based on an average trading volume of 1,470,000 shares, the days-to-cover ratio is currently 2.4 days. Currently, 4.4% of the company's stock are short sold. View VBI Vaccines' Current Options Chain.
Who are some of VBI Vaccines' key competitors?
Some companies that are related to VBI Vaccines include Magenta Therapeutics (MGTA), Innate Pharma (IPHYF), BioSpecifics Technologies (BSTC), DURECT (DRRX), XBiotech (XBIT), Lexicon Pharmaceuticals (LXRX), Kiniksa Pharmaceuticals (KNSA), ImmunoGen (IMGN), Kadmon (KDMN), Obseva (OBSV), AC Immune (ACIU), Prothena (PRTA), CytomX Therapeutics (CTMX), Neptune Wellness Solutions (NEPT) and CymaBay Therapeutics (CBAY).
What other stocks do shareholders of VBI Vaccines own?
Who are VBI Vaccines' key executives?
VBI Vaccines' management team includes the folowing people:
- Mr. Jeff R. Baxter, CEO, Pres & Director (Age 58)
- Dr. David Evander Anderson, Chief Scientific Officer (Age 49)
- Dr. Francisco Diaz-Mitoma, Chief Medical Officer (Age 64)
- Mr. Christopher McNulty, CFO & Head of Bus. Devel. (Age 42)
- Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 54)
How do I buy shares of VBI Vaccines?
Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is VBI Vaccines' stock price today?
One share of VBIV stock can currently be purchased for approximately $0.52.
How big of a company is VBI Vaccines?
VBI Vaccines has a market capitalization of $92.69 million and generates $3.36 million in revenue each year. The biopharmaceutical company earns $-63,600,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. VBI Vaccines employs 108 workers across the globe.View Additional Information About VBI Vaccines.
What is VBI Vaccines' official website?
How can I contact VBI Vaccines?
VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected]
MarketBeat Community Rating for VBI Vaccines (NASDAQ VBIV)
MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe VBIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
